Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
1. A method of preparing a compound of Formula (IIIa):
a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprising reacting a compound of Formula (F) or a salt thereof with a compound of Formula (G) or a salt thereof to generate said compound of Formula (IIIa) or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing:
wherein in each of said formulae:
one of Y 1 and Y 2 is N and the other is CH;
each R 1 is independently chosen from (CR 2 ) k —O—(CR 2 ) m (CR) n (Ring A) n+1 groups,
wherein each Ring A is independently chosen from C 3 -C 10 cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C 1 -C 2 alkyl groups, halogenated C 1 -C 2 alkyl groups, and halogens, and
wherein each R is independently chosen from H, OH, and C 1 -C 2 alkyl groups optionally substituted with one or more halogens;
each R 2 is independently chosen from C 1 -C 2 alkyl groups, OH, C 1 -C 2 alkoxy groups, halogens, and cyano;
each R 3 is independently chosen from C 1 -C 2 alkyl groups optionally substituted with one or more OH groups;
each R 4 is independently a halogen
X a is chosen from F or Cl;
each k is independently 0 or 1;
each r is independently 0 or 1;
each m is independently 0, 1, 2, or 3;
each n is independently 0 or 1;
each p is independently 0, 1, 2, 3, 4, or 5; and
each q is independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.
2. The method of claim 1 , wherein each Y 2 is independently N; and each Y 1 is independently CH.
3. The method of claim 1 , wherein said reacting a compound of Formula (F) or a salt thereof with a compound of Formula (G) or a salt thereof is performed in the presence of a base.
4. The method of claim 1 , wherein a salt of compound of Formula (G) is employed.
5. The method of claim 4 , wherein said salt of compound of Formula (G) is a HCl salt of a compound of Formula (G).
6. A method of preparing a compound of the following formula:
or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprising reacting a compound of Formula (F-1) or a salt thereof, wherein X a is chosen from F or Cl, with a compound of Formula (G-1) or a salt thereof to generate said compound or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing:
7. The method of claim 6 , wherein said reacting a compound of Formula (F-1) or a salt thereof with a compound of Formula (G-1) or a salt thereof is performed in the presence of a base.
8. The method of claim 6 , wherein a salt of compound of Formula (G-1) is employed.
9. The method of claim 8 , wherein said salt of compound of Formula (G-1) is a HCl salt of a compound of Formula (G-1).
10. A method of preparing a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprising reacting a compound of Formula (L) or a salt thereof with NR* 3 :
wherein in each of said formulae:
—X is NH or N(C 1 -C 4 alkyl);
one of Y 1 and Y 2 is independently N and the other is independently CH;
each R 1 is independently chosen from (CR 2 ) k —O—(CR 2 ) m (CR) n (Ring A) n+1 groups,
wherein each Ring A is independently chosen from C 3 -C 10 cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C 1 -C 2 alkyl groups, halogenated C 1 -C 2 alkyl groups, and halogens, and
wherein each R is independently chosen from H, OH, and C 1 -C 2 alkyl groups optionally substituted with one or more halogens;
each R 2 is independently chosen from C 1 -C 2 alkyl groups, OH, C 1 -C 2 alkoxy groups, halogens, and cyano;
each R 3 is independently chosen from C 1 -C 2 alkyl groups optionally substituted with one or more OH groups;
each R 4 is independently a halogen
R* is H or C 1 -C 4 alkyl;
X a is chosen from F or Cl;
each k is independently 0 or 1;
each r is independently 0 or 1;
each m is independently 0, 1, 2, or 3;
each n is independently 0 or 1;
each p is independently 0, 1, 2, 3, 4, or 5; and
each q is independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.